Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

A proposal for radical changes in the drug-approval process.

Wood AJ.

N Engl J Med. 2006 Aug 10;355(6):618-23. No abstract available. Erratum in: N Engl J Med. 2006 Dec 21;355(25):2712.

2.

Dermatology clinical trials and drug development.

Ehrenberger HE, Joshi TG.

Dermatol Nurs. 2003 Oct;15(5):428-34. Review. No abstract available.

PMID:
14619320
3.

Two-stage drug approval would reduce the risks.

Frantz JA.

Nature. 2005 May 12;435(7039):143. No abstract available.

PMID:
15889063
4.

[FDA's new drug approval system].

Ishii A.

Gan To Kagaku Ryoho. 1995 Aug;22(9):1146-51. Review. Japanese. No abstract available.

PMID:
7661565
5.

Drug safety on trial.

[No authors listed]

Nature. 2005 Mar 31;434(7033):545. No abstract available.

PMID:
15800579
6.

FDA introductory comments: clinical studies design and evaluation issues.

Woodcock J.

Clin Trials. 2005;2(4):273-5. No abstract available.

PMID:
16281424
7.

Drug safety special: the safety catch.

Wadman M.

Nature. 2005 Mar 31;434(7033):554-6. No abstract available.

PMID:
15800591
8.

Improving how we evaluate the toxicity of approved drugs.

Reidenberg MM.

Clin Pharmacol Ther. 2006 Jul;80(1):1-6. Epub 2006 Jun 8. Review. No abstract available.

PMID:
16815311
9.

The FDA's drug review process: ensuring drugs are safe and effective.

Meadows M.

FDA Consum. 2002 Jul-Aug;36(4):19-24. No abstract available.

10.

Drug development process for a product with a primary pediatric indication.

Allen AJ, Michelson D.

J Clin Psychiatry. 2002;63 Suppl 12:44-9.

PMID:
12562061
11.

Faster evaluation of vital drugs.

Kessler DA, Feiden KL.

Sci Am. 1995 Mar;272(3):48-54. Review. No abstract available.

PMID:
7871409
12.

[From molecule to medicine--drug development].

Bruhn C.

Dtsch Med Wochenschr. 2010 Feb;135(6):p5. doi: 10.1055/s-0030-1247669. Epub 2010 Feb 11. German. No abstract available.

PMID:
20151355
13.

The generic drug approval process.

Rheinstein PH.

Am Fam Physician. 1993 Dec;48(8):1357-60. No abstract available.

PMID:
8249762
14.

U.S. Food and Drug Administration drug approval: slow advances in obstetric care in the United States.

Wing DA, Powers B, Hickok D.

Obstet Gynecol. 2010 Apr;115(4):825-33. doi: 10.1097/AOG.0b013e3181d53843.

PMID:
20308845
15.

FDA guidance document on monitoring delayed adverse events a good first start.

Williams DA.

Mol Ther. 2005 Dec;12(6):991-2. Epub 2005 Nov 3. No abstract available.

PMID:
16271514
16.

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.

Bunney WE Jr, Azarnoff DL, Brown BW Jr, Cancro R, Gibbons RD, Gillin JC, Hullett S, Killam KF, Kupfer DJ, Krystal JH, Stolley PD, French GS, Pope AM.

Arch Gen Psychiatry. 1999 Apr;56(4):349-52. No abstract available.

PMID:
10197830
17.

Experimental use and the Orphan Drug Act: a biotechnology conundrum.

Koivuniemi PJ.

Nat Biotechnol. 1996 Apr;14(4):511-2. No abstract available.

PMID:
9630930
18.

Drug safety. Gaps in the safety net.

Couzin J.

Science. 2005 Jan 14;307(5707):196-8. No abstract available.

PMID:
15653480
19.

Protecting the health of the public--Institute of Medicine recommendations on drug safety.

Psaty BM, Burke SP.

N Engl J Med. 2006 Oct 26;355(17):1753-5. Epub 2006 Oct 9. No abstract available.

20.

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Lexchin J.

CMAJ. 2005 Mar 15;172(6):765-7. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk